Puriblood Medical Co., Ltd.
TWO: 6847.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Yanwen Chen
- Employees
- 44
- Headquarters
- Hsinchu City, Taiwan
- IPO year
- 2021
- Market cap
- NT$920.7M
- Website
- https://www.puriblood.com
Loading 6847…
Loading profile data…Frequently asked questions about 6847
What does Puriblood Medical Co., Ltd. (6847.TWO) do?
Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In ad...
Where does 6847.TWO trade?
Puriblood Medical Co., Ltd. (6847.TWO) trades on the Taipei Exchange.
What sector is 6847.TWO in?
Puriblood Medical Co., Ltd. (6847.TWO) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Puriblood Medical Co., Ltd.?
Yanwen Chen is the chief executive officer of Puriblood Medical Co., Ltd. (6847.TWO).
Where is Puriblood Medical Co., Ltd. headquartered?
Puriblood Medical Co., Ltd. is headquartered in Taiwan.
Does 6847.TWO pay a dividend?
Puriblood Medical Co., Ltd. (6847.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6847.TWO go public?
Puriblood Medical Co., Ltd. (6847.TWO) completed its initial public offering in 2021.